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Methods: The risk of progression to dementia was estimated using two logistic regression models
based on 250 MCI participants: the first included standard clinical measures (demographic, clinical,
and imaging test information) without CSF biomarkers, and the second included standard clinical
measures with CSF biomarkers.
Results: Adding CSF improved predictive accuracy with 0.11 (scale from 0–1). Of all participants,
136 (54%) had a change in risk score of 0.10 or higher (which was considered clinically relevant), of
whom in 101, it was in agreement with their dementia status at follow-up.
Discussion: An individual person’s risk of progression from MCI to dementia can be improved by
relying on CSF biomarkers in addition to recommended clinical and imaging tests for usual care.
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Diagnostic research criteria for Alzheimer’s disease (AD)
have recommended the use of cerebrospinal fluid (CSF) bio-
markers to determine etiology and prognosis in persons with
mild cognitive impairment (MCI) [1–3]. Because the
recommended clinical diagnostic workup already contains
much information to identify the risk of dementia
progression, it is important to estimate the added value of
CSF biomarkers for AD, relative to clinical assessment
and brain imaging.
Previous research [4–10] has indicated the increased
accuracy when using CSF measures in addition to
neuropsychological tests or magnetic resonance imaging
(MRI) atrophy scores to predict progression to AD-type
dementia in persons with MCI. However, their generaliz-
ability to clinical practice was limited for three reasons. First,
most relied on odds ratios, receiver operating characteristic
(ROC) curves, and sensitivity and specificity outcome mea-
sures. These measures typically reflect the performance of a
model to test if improvements are significant and valuable
for research purposes [11]. However, it is difficult to deter-
mine whether significant improvements in such performance
indicators are clinically relevant. Therefore, alternative out-
comesmeasures have been developed such as the reclassifica-
tion table or the reclassification index. These measures
distinguish between false-positive and false-negative out-
comes, which likely are differently weighted in clinical prac-
tice [11]. Second, the previous research limitedly reflected the
test information that is available from the standard usual care
diagnostic workup. Some of the previous research [3,7] did
not consider the degree of cognitive performance on
neuropsychological test results reflecting the degree of
cognitive performance and did not focus on the added value
or were mainly for methodological purposes, respectively.
Other previous research [4,5,9] selected the best model
based on statistical significance omitting information
available in standard practice (such as demographics and
neuropsychological tests). Other previous research [6,8]
only analyzed CSF in addition to neuropsychological test or
CSF in addition to MRI. Omitting information from the
standard diagnostic workup reduces the generalizability to
practice and possibly overestimated the added value of CSF
because nonsignificant measures could still contribute as
covariates to the overall predictive value of a model when
applied in practice. Third, all previous research focused on
progression to AD-type dementia while progression to other
dementia subtypes is also relevant in clinical practice.
To enable the translation of findings on CSF biomarkers
in the research setting to clinical practice, we approached
CSF biomarkers as a risk factor to predict individual risks
of progression from MCI to any-type dementia in addition
to measures available in usual care diagnostic workup. We
aimed to determine the added clinical value of CSF
biomarkers relative to clinical and imaging tests that are rec-
ommended in usual care, to predict progression to dementia.2. Methods
2.1. Study participants
We selected participants with MCI who consecutively
attended a memory clinic from a range of cohorts in various
European countries: the Development of Screening Guide-
lines and Clinical Criteria for Predementia AD (DESCRIPA)
multicenter study [12] (inclusion between 2003 and 2005,
with an additional sample of participants seen outside theDE-
SCRIPA inclusion period at one of the sites VUmedical cen-
ter (VUmc), inclusion between 1998 and 2007 [13]), LEARN
multicenter study [14] (inclusion between 2009 and 2011),
Ljubljana UniversityMedical Centre [15] (inclusion between
2011 and 2014), and Karolinska University Hospital Hud-
dingememory clinic [16] (inclusion between 2007 and 2011).
Eligibility criteria for each cohort separately are described
elsewhere [4,12,14,15,17]. Inclusion criteria for the
present study were new referral to a memory clinic
because of cognitive complaint; age 50 years or older;
baseline diagnosis of MCI; baseline data of CSF markers
of amyloid b 1–42 (Ab1–42), total tau (t-tau), and
phosphorylated tau (p-tau) levels; at least one follow-up mea-
surement with information on progression to dementia; and
no diagnosis of a somatic psychiatric or neurological disorder
that might have caused the cognitive impairment at baseline.
We excluded two participants with CSF t-tau values more
than five times the absolute deviation to the median t-tau in
the sample, leaving 250 participants for the analyses.
Local ethical committees approved the studies, and all
participants provided informed consent to use their data.
MCI was either diagnosed by a clinician according to the
criteria as applied in usual practice (Petersen [18] for
LEARN and Ljubljana, and Winblad [19] for Karolinska)
or by a researcher using the criteria by Petersen [18] opera-
tionalized as a score lower than 21.5 standard deviation on
standardized neuropsychological examination results
(DESCRIPA and VUmc sample). Not all persons who as-
sessed the diagnosis were blind for the CSF analyses as
part of the CSF results were used for clinical purposes.2.2. Clinical measures
Clinical measures were selected when recommended in
clinical guidelines [20] and when available to the authors.
Demographic information included age, gender, and years
of education. Overall cognition was measured by the
Mini–Mental State Examination (MMSE). Memory perfor-
mance was measured by delayed recall of a Word Learning
Test (WLT) (Rey Auditory Verbal Learning Test [RAVLT]
[21] for the Karolinska, LEARN, and VUmc samples; the
California Verbal Learning Test [22] for the Ljubljana sam-
ple; and for the DESCRIPA sample, the RAVLTand CERAD
[23] were key tests). Raw scores were transformed to a
z-score by adjusting them for age, gender, and/or education
using norm scores from healthy control cohorts outside this
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harmonized to the same outcome. Depressive symptoms
were measured by various scales and were categorized into
three groups as “mild” if 14  Beck Depression Inventory
 19 or 5  Geriatric Depression Scale  8 or
8  Hamilton Depression Rating Scale  14 or
7  Cornell Scale for Depression  9 or 7  Montgomery
Asberg Depression Rating Scale  19; “no” if lower than
these ranges; and “high” if higher than these ranges.
2.3. Imaging measures
All participants underwent MRI at baseline. A qualitative
rating of medial temporal lobe atrophy (MTA) was per-
formed on the MRI [24] with the scores of the right and
left side summed (0–8).
2.4. CSF measures
CSF samples were obtained at baseline by lumbar punc-
ture, stored between 280C and 270C in polypropylene
tubes, and analyzed in the laboratory of the VU Medical
Centre (VUmc center cohort and LEARN), the laboratory
in Gothenburg (DESCRIPA study), the laboratory in Karo-
linska University Hospital Huddinge (for the Karolinska
sample), and the Laboratory in Ljubljana UniversityMedical
Center (for the Ljubljana sample). CSF Ab1–42, t-tau, and
p-tau concentrations were measured in all laboratories using
commercially available sandwich ELISAs (Innotest Ab1–42;
Innotest hTAU-Ag; Innogenetics, Ghent, Belgium) in a
single batch within each of the four laboratories. CSF pro-
cedures of each cohort are described in detail elsewhere
[4,16,25].
2.5. Outcome measures
The main outcome measure was clinical diagnosis of de-
mentia at follow-up (mean follow-up 26 months) according
to the Diagnostic and Statistical Manual of Mental
Disorders, Fourth Edition, Text Revision (DSM-IV-TR):
Diagnostic and statistical manual of mental disorders [26].
Etiology was diagnosed using NINCDS-ADRDA criteria
[27] for AD, NINCDS-AIREN criteria [28] for vascular de-
mentia, McKeith criteria [29] for Lewy body dementia, and
Neary criteria [30] for frontotemporal lobe dementia. This
diagnosis was set by an experienced specialist in dementia
during each of the annual clinical follow-up measurement
moments in which the participant’s physical, neurological,
psychiatric, and neuropsychological status was evaluated
based on the same clinical measurement scales as at baseline
(often except for MRI and CSF tests).
2.6. Statistical analysis
Missing values occurred on years of education (n 5 3,
1.2%), MMSE (n5 2, 0.8%),WLT (n5 44, 17.6%), depres-
sion (n 5 51, 20.4%), and MRI MTA (n 5 27, 10.8%).Students’ t-tests revealed that MMSE, Ab, t-tau, and p-tau
significantly differed between cases with and without
missing WLT scores, that Ab significantly differed between
cases with and without missing depressive symptom scores,
and that WLT significantly differed between cases with and
without missing MTA scores. Therefore, missing data were
not missing completely at random and were imputed using
multiple imputation in the statistical software package
STATA12 to generate 10 imputed data sets. This was done
using chained equations—for each variable, a linear regres-
sion model was built using all other variables as predictors.
In an iterative approach, each missing value was replaced
with a predicted value. To ensure each predicted value was
within the plausible distribution, the predicted value was
matched to a closest observed value within the sample.
The latter was done including random variation to ensure
each imputed value varied across the 10 imputed data sets.
This increased the uncertainty of the outcomes due to the un-
certainty of the actual value of the missing data. Visual eval-
uation of the convergence plots and histograms indicated
valid imputed values following the same distribution as in
the observed data (see Supplemental Material 1).
Two logistic regression prediction models were devel-
oped using statistical software package R version 3.2.5
[31] to determine the risk of progression to any type of
dementia. In the first model, we included all available stan-
dard clinical measures (i.e., age, gender, education, MMSE,
WLT, depressive symptoms, and MRI MTA) without CSF
biomarkers. In the second model, we included the same
available standard clinical measures with the CSF bio-
markers concentrations on Ab1–42, t-tau, and p-tau on a
continuous scale. For each participant, we calculated a risk
score of developing any-type dementia, based on the pre-
dicted values by the logistic regression model without CSF
as well as based on the model with CSF. A memory clinic
center was included as a random intercept to correct for cen-
ter differences. The difference between the two models
(meaning, adding the three CSF markers as a block to the
first model) was tested for significance using a Wald test in
the statistical software package STATA12.
Model performance was assessed by the concordance in-
dex (c-index, which equals the area under the ROC curve;
confidence interval was estimated using the “rcorrcens”
function from the “Hmisc” package (version 3.17-4) in the
statistical software package R). The change in predicted
probability of progression to dementia was calculated by
subtracting the predicted probability based on the first model
(a value between 0 and 1) from the predicted probability
based on the second model. A positive difference reflected
an increased risk due to CSF test outcomes, whereas a nega-
tive value reflected a decreased risk due to CSF test out-
comes. Participants who had an increased risk and in
whom progression to dementia was observed within the
follow-up period were labeled as “correctly reclassified,”
as well as the participants who had a decreased risk and in
whom no progression to dementia was observed. The Net
Table 1
Baseline characteristics and number of observations from 250 participants
before imputation of the sample
Characteristic
Mean (SD)
or n (%) Range
% Missing
values
Age 68.6 (7.5) 52.0 to 89.0 0
Female gender 111 (44%) n/a 0
Education years 11.2 (3.1) 4 to 18 1
MMSE 26.9 (2.4) 18 to 30 1
WLT delayed recall
z-score
21.6 (1.2) 25.6 to 2.3 18
Depression 0.3 (0.6) 0 to 2 20
MRI MTA left and right 2.3 (1.8) 0 to 6 11
CSF Ab1–42 levels, pg/mL 666 (296) 157 to 1538 0
CSF t-tau levels, pg/mL 446 (237) 52 to 1179 0
CSF p-tau levels, pg/mL 71 (30) 16 to 172 0
Conversion to dementia 99 (40%) n/a 0
AD 86 (87%) n/a 0
VAD 4 (4%) n/a 0
DLB 3 (3%) n/a 0
FTD 5 (5%) n/a 0
Other 1 (1%) n/a 0
Time to conversion (months) 26.5 (14.3) 4 to 130.4 0
Abbreviations: SD, standard deviation; n, number of participants;
MMSE, Mini–Mental State Examination; WLT, Word Learning Test;
MRI, magnetic resonance imaging; MTA, medial temporal lobe atrophy;
CSF, cerebrospinal fluid; n/a, not applicable; AD, Alzheimer’s disease;
p-tau, phosphorylated tau; t-tau, total tau; VAD, vascular dementia; DLB,
dementia of lewy bodies; FTD, frontotemporal dementia.
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participants who did convert to dementia (i.e., events) and
who did not convert to dementia (i.e., nonevents). This index
represents the sum of the following two proportions: the
proportion of individuals with an increased risk minus the
proportion with a decreased risk for those with a positive
outcome, and the proportion of individuals with a decreased
risk minus the proportion with an increased risk for those
with a negative outcome [32]. The confidence interval was
estimated using the “reclassification” function from the
“PredictABEL” package (version PredictABEL_1.2-2) in
the statistical software package R.
Both prediction models were validated by visually assess-
ing the relation between the observed and predicted propor-
tion of progression to dementia [33,34] (see Supplemental
Material 2). Furthermore, a bootstrap validation was per-
formed. First, 250 participants were sampled with replace-
ment, and the two models without and with CSF were
fitted to this sampled data. Second, predicted values were
calculated using this bootstrap-based model on the sampled
data and on the original data. The performance difference
between them was averaged over 6500 bootstrap samples
to produce a shrinkage factor, which can be subtracted
from the original model’s performance in the original data
to obtain an optimism-corrected estimate of performance.
In addition to the single measures for model performance
(c-index, proportion correct reclassification, and NRI), we
generated a reclassification table [35] to provide a more
detailed overview of reclassification. Because specific pre-
defined risk categories to guide clinical management upon
have not been reported as far as the authors know, the
changes in risk scores were cut in quintiles. However, cate-
gories based on quintiles are arbitrary because, for example,
a change from 0.19 to 0.21 could result into a reclassification
while it has most probably no effect on clinical management
or impact on the patient. Therefore, a minimum risk change
of 0.10 was assumed clinically relevant. As an alternative to
the reclassification table, the change in predicted probability
was classified and tabulated.3. Results
Two hundred fifty participants met the inclusion criteria.
Table 1 presents the baseline characteristics. The participants
were on average 68.6 years old (standard deviation 5 7.5)
and consisted of 111 (44%) females. Median follow-up
time for the 151 (60%) nonconverters was 24 months
(mean5 26; range 7–87) and 24months for the 99 (40%) de-
mentia converters (mean5 27; range 4–130). The proportion
of progression to AD-type dementia among the converters
was 87%, for vascular dementia (VAD) 4%, for dementia
of lewy bodies (DLB) 3%, for frontotemporal dementia
(FTD) 5%, and for other types of dementia 1%.
Table 2 summarizes the univariate logistic regression results
and the results of themultivariate predictionmodel without and
with CSF. In the model without CSF, female gender, lowerMMSE, and higher MTA scores significantly predicted pro-
gression to any-type dementia. The model including CSF
Ab1–42, t-tau, and p-tau markers was significantly better than
themodelwithout the threeCSFmarkers (P,.001;F5 12.93).
The concordance index of the model without CSF was
0.741 (95% confidence interval [CI]: 0.679–0.802) and
with CSF 0.851 (95% CI: 0.805–0.896) reflecting an
improved accuracy of 0.11 on a scale from 0 to 1.
Each participant’s riskof progression to any-typedementia
using the model without CSF and the model with CSF is
shown in Fig. 1. The proportion correct reclassifications in
participants who converted to dementia was 0.70 (95% CI:
0.64–0.76) and in participants who did not convert to demen-
tiawas 0.72 (95%CI: 0.66–0.78). This indicates that of the 99
participants who progressed to dementia (represented by both
filled green circles and filled red triangles in Fig. 1), 69 (70%)
participants received a higher risk after CSF testing compared
with those received risk before CSF testing (represented by
filled green circles in Fig. 1). For the 151 participants who
did not progress to dementia (open green circles and open
red triangles in Fig. 1), 109 (72%) received a lower risk after
CSF testing (open green circles in Fig. 1). Furthermore, 54%
of the participants’ risk scores changedmore than 0.10, which
is reflected by the fact that most reclassifications fell outside
the gray-shaded area around the diagonal in Fig. 1.
The NRI was 0.40 (95% CI: 0.26–0.55) within the partic-
ipants who converted to dementia and 0.09 (95% CI:20.01
to 0.19) within the participants who did not convert to de-
mentia, when classifying risks into categories of quintiles
Table 2
Logistic regression results for any-type dementia prediction using the model without and with CSF biomarkers
Predictor
Univariate Multivariate model without CSF Multivariate model with CSF
OR (95% CI) P value OR (95% CI) P value OR (95% CI) P value
Intercept n/a n/a 0.33 (0.00–74.04) .686 10.61 (0.01–7617.88) .481
Age (years) 1.05 (1.01–1.09) .015 1.03 (0.98–1.08) .249 0.99 (0.94–1.05) .764
Female gender 1.94 (1.12–3.35) .018 2.15 (1.12–4.13) .021 1.48 (0.70–3.12) .299
Education (years) 1.03 (0.94–1.12) .531 1.10 (0.99–1.22) .073 1.06 (0.94–1.19) .367
MMSE 0.83 (0.73–0.94) .003 0.84 (0.73–0.98) .025 0.84 (0.70–1.00) .046
Word learning test (z-score) 0.69 (0.53–0.91) .007 0.76 (0.56–1.04) .084 0.82 (0.57–1.20) .307
Depression 0.84 (0.49–1.44) .535 0.95 (0.51–1.74) .857 0.99 (0.52–1.89) .970
MRI MTA left and right 1.43 (1.20–1.71) .000 1.39 (1.12–1.71) .003 1.49 (1.16–1.91) .002
CSF Ab1–42 1.00 (0.99–1.00) .000 n/a n/a 1.00 (1.00–1.00) .000
CSF t-tau 1.00 (1.00–1.01) .000 n/a n/a 1.00 (1.00–1.00) .453
CSF p-tau 1.03 (1.02–1.04) .000 n/a n/a 1.02 (0.99–1.04) .219
Abbreviations: CSF, cerebrospinal fluid; OR, odds ratio; CI, confidence interval; MMSE, Mini–Mental State Examination; MRI, magnetic resonance
imaging; MTA, medial temporal lobe atrophy; n/a, not applicable; t-tau, total tau; p-tau, phosphorylated tau.
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progressed to dementia, 55 were correctly classified in a
higher risk category after CSF testing and 15 were incor-
rectly classified in a lower risk category after CSF testing,Fig. 1. Dementia risk score of each participant based on the logistic regressionmod
measures. Participants in whom the predicted risk increased with CSF, compared to
whom the risk decreased in the bottom right. Filled dots represent participants who
convert. Increased risks by adding CSF were considered correct if the participant c
(open red triangle), and vice versa for decreased risks. The gray area indicates a 1
cerebrospinal fluid.resulting in 40 (40% of all participants who progressed)
net correctly reclassified participants. For the 151 partici-
pants who did not progress to dementia, 37 were correctly
and 23 incorrectly reclassified, resulting in 14 (9% of allel without CSF (x-axis) and with CSF (y-axis) in addition to standard clinical
the risk without CSF, are presented in the top left of the diagonal line, and in
converted to dementia at follow-up and open dots participants who did not
onverted (filled green circle) and incorrect if the participant did not convert
0% or less change in pre- and post-CSF dementia risk. Abbreviations: CSF,
Table 3
Reclassification table representing the number of participants in each risk category based on the risk predictionmodel (rows) without CSF and the risk prediction
model with CSF (columns) in addition to standard clinical measures for the total group (A) and split up into nonconverters (B) and converters (C)
Dementia risk classification without CSF
Dementia risk classification with CSF
Reclassified n (%) Correctly reclassified n (%)QU1 QU2 QU3 QU4 QU5
(A) Reclassification in the total sample
QU1 83 14 10 1 0 25 (23) 13 (52)
QU2 35 24 19 11 2 67 (74) 50 (75)
QU3 7 8 7 10 3 28 (80) 21 (75)
QU4 1 0 1 6 8 10 (63) 8 (80)
QU5 0 0 0 0 0 n/a n/a
(B) Reclassification in the sample of subjects not converted to dementia
QU1 75 7 5 0 0 12 (14) 0 (0)
QU2 26 13 7 1 0 34 (72) 26 (76)
QU3 5 5 2 2 0 12 (86) 10 (83)
QU4 1 0 0 1 1 2 (67) 1 (50)
QU5 0 0 0 0 0 n/a n/a
(C) Reclassification in the sample of subjects converted to dementia
QU1 8 7 5 1 0 13 (62) 13 (100)
QU2 9 11 12 10 2 33 (75) 24 (73)
QU3 2 3 5 8 3 16 (76) 11 (69)
QU4 0 0 1 5 7 8 (62) 7 (88)
QU5 0 0 0 0 0 n/a n/a
Abbreviations: CSF, cerebrospinal fluid; n, number of participants; QU1 to QU5 represent the five quintiles with probabilities [0%, 20%), [20%, 40%), [40%,
60%), [60%, 80%), and [80%, 100%], respectively; n/a, not applicable.
NOTE. The last two columns present the total number and percentage of reclassifications and the proportion of correct reclassifications (i.e., reclassified into
higher risk category and observed dementia progression, or reclassified into a lower risk category and no observed dementia progression). For example, 91
participants received a risk score between 0.20 and 0.40. Of them, 67 (74%) were reclassified of whom 35 to a lower risk category (26 eventually converted
and 9 did not) and 32 to a higher risk category (24 eventually converted and 8 did not).
Table 4
Participants categorized by their change in risk score between the prediction
model without CSF and the predictionmodel with CSF and the proportion of
progression to any-type dementia
Risk change
n (% of total
sample)
n,
conversion
n, no
conversion
Increased risk of dementia conversion
0%  change , 10% 36 (14%) 17 (47%) 19 (53%)
10%  change , 25% 41 (16%) 23 (56%) 18 (44%)
25%  change , 50% 32 (13%) 27 (84%) 5 (16%)
50%  change  100% 2 (1%) 2 (100%) 0 (0%)
Total clinically relevant
(change  10%)
75 (30%) 52 (69%) 23 (31%)
Decreased risk of dementia conversion
0%  change , 10% 78 (31%) 18 (23%) 60 (77%)
10%  change , 25% 46 (18%) 9 (20%) 37 (80%)
R.L.H. Handels et al. / Alzheimer’s & Dementia 13 (2017) 903-912908participants who did not progress) net correct reclassified
participants.
Table 3 summarizes the number of reclassifications of
risk categories (i.e., quintiles) after using the prediction
model with CSF compared with the prediction model
without CSF for the total sample and for the subgroup of par-
ticipants who did and did not convert to dementia. Partici-
pants with a risk score between 0.40 and 0.60 (i.e., third
quintile) were most often reclassified (80%). Reclassifica-
tions were most often correct (80%) in participants with a
risk score between 0.60 and 0.80.
Table 4 describes the proportions of participants in each
category of risk change from the prediction model without
CSF to the prediction model with CSF. Of all participants
136 (54%) had a change in risk score of 0.10 or higher, which
was considered clinically relevant. Of these 136, 52
correctly received an increased risk after CSF (because
they were converted to dementia at follow-up), and 49
correctly received a decreased risk. Respectively, 23 incor-
rectly received an increased risk after CSF because they
did not convert to dementia at follow-up, and 12 incorrectly
received a decreased risk.25%  change , 50% 15 (6%) 3 (20%) 12 (80%)
50%  change  100% 0 (0%) n/a n/a
Total clinically relevant
(change  10%)
61 (24%) 12 (20%) 49 (80%)
Abbreviations: CSF, cerebrospinal fluid; n, number of participants; n/a,
not applicable.4. Discussion
We evaluated the added value of CSF biomarkers to a
prognostic prediction model consisting of demographic,clinical, and imaging information for progression to any-
type dementia in a memory clinic sample of 250 participants
with MCI. Our results indicated that adding CSF biomarkers
to the usual care diagnostic workup improved the ability to
differentiate between those who do and do not progress to
dementia with 0.11 on a scale from 0 to 1 (concordance
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indicates full predictive ability). In 40% of all participants,
the dementia risk score changed and showed a correct clin-
ically relevant increased or decreased risk score of 0.10
(on a risk scale of 0–1) or more after CSF biomarkers
were added to the prediction model. However, 26% of the
participants were incorrectly reclassified with a risk change
of 0.10 or more, which might result into incorrect prognostic
disease management.
The addition of CSFmarkers to the model resulted mostly
in reclassifications of individuals who had a midrange risk
score for dementia (between 0.20 and 0.60). If one adopts
the assumption that persons with an improved individual
risk score experience less feelings of uncertainty because
they have better knowledge on what to expect in the future,
then CSF can to, a limited extent, improve a person’s well-
being related to certainty. For example, addition of CSF
markers was, in particular, useful to identify persons with
a low risk for short-term decline because in a large group
of participants, the post-CSF risk reduced and fell between
0.00 and 0.10.
After using CSF biomarkers, 54% of all participants
received a dementia risk change that was considered clini-
cally relevant. Still, 46% of the risk changes caused by
CSF were lower than 0.10, which was considered clinically
irrelevant. This urges a careful selection in performing a
lumbar puncture for clinical purposes to ensure relevant
risk changes and prevent unnecessary exposure to lumbar
puncture adverse events. From the results of this study, a
clinically relevant and correct risk change occurred most
often in participants with a pre-CSF risk between 20% and
60%. Furthermore, post hoc analyses identified various sub-
groups of clinically relevant and correct risk changes, using
Students’ t-test and chi-square tests (P , .05). Participants
with a risk change in risk score of 0.10 had a significantly
higher age (70 vs. 68), lower MMSE (26 vs. 28), and higher
MTA score (2.6 vs. 1.9) compared to participants with a
change in risk score lower than 0.10. Participants with a clin-
ically relevant correct reclassification had a significantly
lower age (69 vs. 72) and were more likely female (56%
vs. 29%) compared to participants with a clinically relevant
incorrect reclassification. These identified subgroups, how-
ever, only show subtle differences. Therefore, future
research should more precisely identify subgroups of partic-
ipants with correct reclassifications based on sets of multiple
characteristics, for example, using cluster analysis such as
by van Giessen et al. [36].
Various studies have evaluated the predictive value of
CSF in addition to clinical markers and MRI in participants
with MCI using a prediction model [4–8]. All reported a
significant improvement in predictive accuracy when
relying on CSF biomarkers. However, as explained in
Section 1, the models used in these studies omit test informa-
tion from the standard diagnostic workup making their
results not generalizable to medical practice. In addition,our study showed 54% relevant reclassifications of which
75% correctly. This detailed information enables clinicians
to judge whether the benefits outweigh the harms (46% irrel-
evant changes and 26% of all relevant changes incorrect, as
well as possible lumbar puncture side effects). Our study
also differed by using dementia risk predictions on a contin-
uous scale allowing more subtle reclassifications instead of
cutoff-based dichotomized risk classifications because we
considered a risk change of 10% or more as clinically rele-
vant. Because the results indicated an added value of CSF
biomarkers on this risk, it suggests that the common search
for optimal cutoff scores in biomarker research to dichoto-
mize persons as either positive or negative undervalues the
complexity and uncertainty in actual practice.4.1. Limitations
The sample size was moderately large and included 99
dementia progression events for 10 predictor variables,
which could have led to an overfitted model. Therefore,
our results must be validated in an external cohort. Neverthe-
less, participants were recruited from different centers, over
a large time period (1998–2014) and using different inclu-
sion criteria, making it generalizable to this heterogeneous
population. However, generalizability to old age might be
limited as the average age was 69 years, and diagnostic per-
formance has been shown to decrease with age [37], and a
40% a priori risk is higher than other observed proportions
[38].
The average follow-up period of 26 months may have
been too short to observe all progressions to AD-type de-
mentia (lowering the probability of progression in CSF
positive) and also too short to observe other-type demen-
tia progression (also lowering the probability of progres-
sion in CSF negative). Furthermore, the follow-up
duration might impact reclassifications due to CSF. There-
fore, these risk predictions are only generalizable to the
study’s average follow-up period of 26 months. To check
the stability of the results, the model performance was
analyzed in a subsample of participants with at least 12-
month follow-up (95%). All model performance out-
comes were similar to the original analyses and did not
change the conclusions of this study (the largest change
was the NRI in participants who did not convert to demen-
tia and was 0.23 instead of 0.25 in the original analyses).
Post hoc analysis on participants with at least 24-month
follow-up (60%) also resulted in a significant added value
of CSF biomarkers, although there was a smaller improve-
ment in c-index.
Data on clinical history, neurological and physical ex-
amination, activities of daily living, comorbidities, and
blood tests were not available for some of the data samples.
This limited the extent to which this study reflects clinical
practice and could have led to an overestimation of the
added value of CSF biomarkers as the missing clinical
R.L.H. Handels et al. / Alzheimer’s & Dementia 13 (2017) 903-912910and diagnostic variables could increase the predictive value
of the prediction model without CSF. A study by Handels
et al. [39] found no added value of CSF biomarkers when
added to patient vignettes presenting all test information
from the standard diagnostic workup in a memory clinic.
They simulated prognostic decision making by a panel of
clinical experts instead of using a risk prediction model
and concluded that the standard workup probably appeared
already sufficient for them to predict short-term decline
fairly accurately.
The results of this study relied on the assumption that a
risk change of 0.10 was clinically relevant, over the full
range of prior probabilities (between 0 and 1). Possibly,
the relevance of a change is dependent on its prior probabil-
ity (e.g., a risk change from 0.15 to 0.05 might not change
the clinical conclusion and management, whereas a risk
change from 0.40 to 0.50 does change the clinical conclusion
and management).
Both the timing of the dementia progression and the
possible positive and negative effects of prognostic informa-
tion on patient-important health outcomes were not taken
into account. Future studies, especially on patient-
important outcomes, are required to decide on the position
of CSF in clinical practice, as well as improvements due to
standardization and harmonization [40]. Studies on
patient-important outcomes are ideally performed in a ran-
domized controlled setting measuring the impact of commu-
nicating the diagnostic and prognostic conclusion on patient
well-being [41]. To enable cost-effectiveness studies, we
added Supplemental Material 3 for decision analytic
modeling.
This study followed the argument from the Alzheimer’s
Disease International report [42] that regardless of the cause,
it is the dementia syndrome which is most relevant in the
domain of public health and dementia prevention. Focusing
on AD-type dementia would leave a patient in uncertainty in
case of negative biomarkers as the risk of progression to
other-type dementia is still present. This study takes into ac-
count this risk as, for example, in case of AD-negative CSF
results, progression to any-type dementia can still be indi-
cated by the other markers. The study is, however, limited
as imaging or biomarkers specific to other neurodegenera-
tive diseases such as Lewy body and vascular causes were
not taken into account.4.2. Conclusion
An individual patient’s risk estimation of any-type de-
mentia progression can be improved by adding CSF
biomarker information to clinical and imaging tests as rec-
ommended in usual care.Acknowledgments
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 Systematic review: Publications on diagnostic or
prognostic value of CSF in addition to clinical mea-
sures in MCI were searched in PubMed and in refer-
ences and citations of retrieved relevant publications.
Previous research has indicated increased odds on
progression to AD-type dementia when using CSF
biomarkers in addition to a selected set of clinical
measures.
 Interpretation: In our study, we reflected clinical prac-
tice by reporting clinically relevant reclassification ta-
bles, including an extensive set of clinical measures
used in standard practice and reporting on progression
to any-type dementia. Our findings indicated
improved classification, although this was limited to
40% of the participants.
 Future directions: The critical question remains
whose prognosis improves and whether improved
prognostic (and diagnostic) accuracy causes
improved patient well-being. This needs to be estab-
lished empirically to introduce and reimburse
advanced diagnostics for AD in clinical practice.References
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